Daiichi Pharmaceuticals Co., Ltd. | Search

Accessibility help Skip to navigation Skip to content Skip to footer

Showing results for Daiichi Pharmaceuticals Co., Ltd.

Sort by

Viewing results 1‒25 of 1436

Healthcare
UK partnerships with life sciences groups threatened by NHS pressures
...Gilead has worked with scientists at Accelerated Clinical Trials Ltd to develop a blood cancer treatment....
May 1, 2023
News in-depthDementia
Alzheimer’s drug Leqembi falls short of blockbuster status in faltering US rollout
...“It was one of the most epic episodes ever in pharmaceuticals history: you got an accelerated approval of a product that didn’t have a completed phase 3 trial....
April 22, 2024
FT Live
US Pharma and Biotech Summit
Strategies for innovation, pricing and access
Thursday, 16 MayNew York, NY, USA
Coronavirus treatment
Expired Pfizer Covid antiviral drugs set to cost Europe $2.2bn, data shows
Millions of Paxlovid pills have gone unused as tight controls restrict access
January 1, 2024
Deepmind Technologies Ltd
DeepMind spin-off aims to halve drug discovery times following Big Pharma deals
...Instead, Isomorphic chose to sign deals with just two pharmaceutical companies....
January 10, 2024
Japanese business & finance
Chinese boycott beauty products after Fukushima water discharge
...imports of seafood products from Japan since Tokyo began releasing the water in late August, 12 years after a devastating earthquake and tsunami triggered a meltdown of nuclear reactors at the Fukushima Daiichi...
October 16, 2023
Drugs research
New studies find benefits in very early drug treatment of Alzheimer’s
...But until recently, many large pharmaceutical companies were reluctant to invest heavily in finding treatments after decades of failure....
October 25, 2023
FT Live
Global Pharma and Biotech Summit
Driving life sciences innovation in a disrupted world
Tuesday, 5 NovemberIn-Person & Online Conference
The Weekend Essay
Hauser & Wirth: the Swiss gallery that went global
...The virtue of putting private collections on public display is inculcated in Switzerland’s merchant class, the heirs to textile and pharmaceutical fortunes....
March 2, 2024
Disease control and prevention
Japanese drugmaker urges G7 to fix infectious diseases market
Shionogi chief warns companies are deserting the field to focus on more lucrative areas
August 28, 2023
Artificial intelligence
DeepMind uses AI to predict harmful genetic mutations in humans
...Thomas said she expected AlphaMissense to be used in healthcare as “a co-pilot for clinical scientists, flagging which variants they should be focusing on so that they can do their jobs more efficiently”...
September 19, 2023
News in-depthDrugs research
A pharma partnership that brought a breakthrough in breast cancer
...But Daiichi had never made a cancer drug. “In the end, science won the day back then,” said Ken Takeshita, global head of R&D at Daiichi....
January 6, 2023
Pharmaceuticals sector
Drugmaker warns US data rules threaten access to Alzheimer’s treatment
Japan’s Eisai says it will not finalise Leqembi spending plans until government clarifies financial support
June 17, 2023
Dementia
US regulators approve first drug to slow progression of Alzheimer’s
...It comes after decades during which many big pharmaceutical companies lost hope and cut investment in Alzheimer’s research....
July 6, 2023
Dementia
Two Alzheimer’s drugs offer hope to patients after decades of waiting
...The US Food and Drug Administration in January approved lecanemab, a drug co-developed by Japanese drugmaker Eisai and US biotech Biogen, under an accelerated process....
May 8, 2023
Chinese equities
Pharma and funeral stocks rally as investors ride China’s Covid exit wave
...more than 10 per cent over the past five trading days while Shanghai Fosun Pharmaceutical added 7 per cent....
December 13, 2022
Special ReportAsia-Pacific Innovative Lawyers
In-house legal work: best practice case studies
...Risk management Winner: Johnson & JohnsonOriginality: 8; Leadership: 9; Impact: 9; Total: 26The litigation team in Asia-Pacific designed a digital system for the pharmaceutical business to improve its management...
May 5, 2023
FT Live
Building an AI-First Organisation
How can business leaders use AI to drive value?
Thursday, 25 AprilHôtel Lutetia, Paris, France
Kirin Holdings Co Ltd
Japanese brewer Kirin strikes $1.3bn deal to buy Australian vitamin maker
...Blackmores was established 91 years ago by Maurice Blackmore who co-founded one of the country’s first health stores in Brisbane in 1938....
April 27, 2023
Medical science
AstraZeneca-Daiichi drug sharply raises breast cancer survival rate, trial shows
...“This is not only a breakthrough, it is practice-changing,” said Gilles Gallant, Daiichi’s global head of oncology development....
June 5, 2022
Starling Bank Ltd
Thirty UK premium stocks that have more conflict-of-interest risk than Starling Bank
...That’d be bad news for Hikma Pharmaceuticals (27.2 per cent). What about board chairs and their deputies?...
May 26, 2023
Anjana Ahuja
New Alzheimer’s drug straddles uneasy gulf between help and harm
...That is a step up from current drugs that treat only symptoms: a landmark success in a desert strewn with pharmaceutical failures....
January 11, 2023
Pharmaceuticals sector
US approves Alzheimer’s drug that slows rate of cognitive decline
...Lecanemab, which was co-developed by Tokyo-based Eisai and US biotech Biogen, is a monoclonal antibody that acts by reducing the build-up of sticky plaques in the brain called beta-amyloid....
January 6, 2023
Due Diligence
The next big battleground for the CMA Premium content
...Deutsche Bank has hired Perella Weinberg Partners’ Marie-Soazic Geffroy as global co-head of its financial institutions group, based in Paris....
June 15, 2023
Pharmaceuticals sector
Swedish scientist behind Alzheimer’s drug has big ambitions
...“We want [BioArctic] to be a fully-fledged pharmaceutical company: that is our ambition.”...
December 2, 2022
LexDrugs research
Dementia/Biogen: causal controversy means investors must take a stance Premium content
The early death of an Alzheimer’s patient taking part in lecanemab trials sent shares down
November 28, 2022
Eisai Co Ltd
Japan’s Eisai aims to silence critics over breakthrough Alzheimer’s drug
...Both Roche’s gantenerumab and lecanemab, co-developed by Eisai and Biogen, are monoclonal antibody treatments based on the hypothesis....
November 29, 2022
The editorial board
A glimmer of hope in treating Alzheimer’s disease
...Most Alzheimer’s drug candidates are not discovered by pharmaceutical companies but in academic labs and biotech businesses....
December 2, 2022

Previous pagePage 1 of 58Next page